Additionally, the clinical importance of Akt was demonstrated by elucidating the therapeutic action of the systemic administration of the Akt inhibitor LY294002 on multiple myeloma-mediated osteoclast formation in severe combined immunodeficiency mice 30. This evidence concerns the gene AKT1 and plasma cell myeloma.